BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
BRAF and MEK inhibitor (BRAFi/MEKi) combinations are currently the standard treatment for patients with BRAF<sup>V600</sup> mutant metastatic melanoma. Since the RAS/RAF/MEK/ERK-pathway is crucial for the function of different immune cells, we postulated an effect on their function and t...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
MDPI AG
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/a32262ee3d9641499f4337e4a28eb196 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|